• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer.

作者信息

Wang Bi-Cheng

机构信息

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

出版信息

J Immunother Cancer. 2025 Apr 30;13(4):e012312. doi: 10.1136/jitc-2025-012312.

DOI:10.1136/jitc-2025-012312
PMID:40306959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12049894/
Abstract
摘要

相似文献

1
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer.贝伐单抗联合化疗及抗程序性死亡蛋白1（PD-1）疗法用于一线治疗既往未接受过治疗的转移性三阴性乳腺癌。
J Immunother Cancer. 2025 Apr 30;13(4):e012312. doi: 10.1136/jitc-2025-012312.
2
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.帕博利珠单抗联合化疗用于晚期三阴性乳腺癌的一线治疗。
Future Oncol. 2024;20(22):1587-1600. doi: 10.2217/fon-2023-0301. Epub 2024 Apr 10.
3
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
4
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.基于PD-1/PD-L1免疫检查点阻断的转移性三阴性乳腺癌联合免疫疗法
Int Immunopharmacol. 2022 Dec;113(Pt B):109444. doi: 10.1016/j.intimp.2022.109444. Epub 2022 Nov 16.
5
Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.倡导新的肿瘤学研究范式：贝伐珠单抗在法国队列研究中三阴性乳腺癌的应用模式。
Oncology. 2019;97(1):1-6. doi: 10.1159/000499583. Epub 2019 Apr 2.
6
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.帕博利珠单抗对比研究者选择化疗用于转移性三阴性乳腺癌（KEYNOTE-119）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4.
7
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.贝伐单抗、替雷利珠单抗和白蛋白结合型紫杉醇用于既往未治疗的转移性三阴性乳腺癌：一项II期试验。
J Immunother Cancer. 2025 Apr 8;13(4):e011314. doi: 10.1136/jitc-2024-011314.
8
Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.每周紫杉醇、卡培他滨和贝伐珠单抗联合卡培他滨和贝伐珠单抗维持治疗作为一线治疗三阴性、转移性或局部晚期乳腺癌：来自 GINECO A-TaXel 2 期研究的结果。
Cancer. 2016 Oct 15;122(20):3119-3126. doi: 10.1002/cncr.30170. Epub 2016 Jul 14.
9
Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review.使用PD-1/PDL-1抑制剂治疗转移性三阴性乳腺癌的免疫疗法：一项系统综述。
Oncol Rev. 2021 Dec 6;15(2):497. doi: 10.4081/oncol.2021.497. eCollection 2021 Sep 21.
10
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.HER2阴性转移性乳腺癌一线贝伐单抗联合化疗的选择及临床反应相关因素：ONCOSUR AVALOX研究
Anticancer Res. 2015 Dec;35(12):6941-50.

本文引用的文献

1
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.贝伐单抗、替雷利珠单抗和白蛋白结合型紫杉醇用于既往未治疗的转移性三阴性乳腺癌：一项II期试验。
J Immunother Cancer. 2025 Apr 8;13(4):e011314. doi: 10.1136/jitc-2024-011314.
2
Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis.肝转移癌患者的免疫治疗与肿瘤突变负荷：一项荟萃分析和真实世界队列分析
Front Oncol. 2023 Jan 19;12:994276. doi: 10.3389/fonc.2022.994276. eCollection 2022.
3
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.帕博利珠单抗联合化疗治疗晚期三阴性乳腺癌。
N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.
4
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.